Waverly Advisors LLC Acquires 15,881 Shares of AstraZeneca PLC (NASDAQ:AZN)

Waverly Advisors LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 191.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,155 shares of the company's stock after acquiring an additional 15,881 shares during the period. Waverly Advisors LLC's holdings in AstraZeneca were worth $1,583,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Banque Transatlantique SA purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $26,000. Albion Financial Group UT increased its holdings in shares of AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after buying an additional 248 shares during the last quarter. CoreCap Advisors LLC raised its position in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after buying an additional 155 shares in the last quarter. Crews Bank & Trust bought a new stake in shares of AstraZeneca during the 4th quarter worth $55,000. Finally, Golden State Wealth Management LLC purchased a new position in AstraZeneca in the fourth quarter worth $55,000. Institutional investors own 20.35% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AZN shares. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley started coverage on AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $88.00.

AstraZeneca Trading Up 0.4%

Shares of AZN stock opened at $69.95 on Friday. The business has a 50-day moving average of $69.91 and a 200 day moving average of $69.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The stock has a market capitalization of $216.93 billion, a PE ratio of 30.95, a P/E/G ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the company posted $2.06 earnings per share. The business's revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.